Pay in 4 interest-free payments of $7.42 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
I previously compared Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO) (NONOF) in August 2025, discussing how the prior compounding/regulatory headwinds had triggered their painful corrections, worsened by Eli Lilly Trumps Novo Nordisk In GLP-1 Race: Multi-Year Growth Prospects Summary Eli Lilly's GLP-1 portfolio outpaces Novo Nordisk's sluggish performance, supported by the former's superior tolerability, strategic distribution partnerships, expanding US market share, and accelerated revenue growth
But this progress comes at a steep financial cost
Youll continue to receive Nooms behavior-change tools, GLP-1 Companion access, and support from a dedicated Care Team
This provides convenience and eliminates healthcare barriers but also removes safety oversight
You can still use the vial, but recalculate your dose using the actual concentration
US$ 22.40
US$ 26.87
US$ 24.68
US$ 29.19
US$ 27.63
